



## Rebetol® (ribavirin) – Product discontinuation

- On April 16, 2019, the [FDA announced](#) the discontinuation of Merck's [Rebetol \(ribavirin\)](#) oral solution.
  - The discontinuation was due to business reasons and is not due to any safety, efficacy or quality issues.
  - Rebetol will be discontinued on or near June 2019.
  - Brand Rebetol capsules will continue to be available. Generic ribavirin is currently available as a tablet and capsule.
- Rebetol in combination with interferon alfa-2b (pegylated and nonpegylated) is indicated for the treatment of chronic hepatitis C in patients  $\geq 3$  years of age with compensated liver disease.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.